- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07342608
Segurança e Desempenho do Elétrodo de Pacing Cardíaco LINEA Otimizado para Implantação no Septo Interventricular (STARLIGHT)
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Antoine Guihard
- Número de telefone: +33 1 46 01 33 20
- E-mail: antoine.guihard@cf.microport.com
Locais de estudo
-
-
-
Ghent, Bélgica
- Recrutamento
- Ghent University Hospital
-
Contato:
- Jan De Pooter
- E-mail: jadpoote.depooter@ugent.be
-
-
-
-
-
Girona, Espanha
- Recrutamento
- Hospital Universitari de Girona Doctor Josep Trueta
-
Contato:
- María Emilce Trucco
- E-mail: metrucco.girona.ics@gencat.cat
-
Granada, Espanha
- Recrutamento
- Hospital Universitario Virgen de las Nieves
-
Contato:
- Manuel Molina
- E-mail: manuel.molina.lerma@gmail.com
-
Valencia, Espanha
- Recrutamento
- Hospital Universitari i Politècnic La Fe
-
Contato:
- Óscar Cano
- E-mail: oscape13@hotmail.com
-
-
-
-
-
Annecy, França
- Recrutamento
- Centre Hospitalier Annecy Genevois
-
Contato:
- Pierre Frey
- E-mail: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, França
- Recrutamento
- CHU Clermont-Ferrand
-
Contato:
- Pierre-Antoine Catalan
- E-mail: pacatalan@chu-clermontferrand.fr
-
Grenoble, França
- Recrutamento
- CHU Grenoble
-
Contato:
- Adrien Carabelli
- E-mail: acarabelli@chu-grenoble.fr
-
Montpellier, França
- Recrutamento
- Clinique du Millénaire
-
Contato:
- Nicolas Clémenty
- E-mail: nicolas.clementy@gmail.com
-
Rouen, França
- Recrutamento
- CHU Rouen Hôpital Charles Nicolle
-
Contato:
- Raphaël Al Hamoud
- E-mail: raphael.al-hamoud@chu-rouen.fr
-
Tours, França
- Recrutamento
- Hôpital Trousseau
-
Contato:
- Arnaud Bisson
- E-mail: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Itália
- Recrutamento
- Ospedale Maggiore della Carità - AO Univ.
-
Contato:
- Gabriele Dell'Era
- E-mail: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Itália
- Recrutamento
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Contato:
- Gianluca Mirizzi
- E-mail: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Portugal
- Recrutamento
- ULS de Coimbra
-
Contato:
- João Ferreira
- E-mail: joaoaferreira29@gmail.com
-
Lisbon, Portugal
- Recrutamento
- ULS Santa Maria
-
Contato:
- Nelson Cunha
- E-mail: nelsoncunha@campus.ul.pt
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: LINHA de cabo de estimulação cardíaca
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Prazo: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Prazo: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Prazo: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Prazo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Prazo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Prazo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Prazo: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Prazo: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Prazo: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Prazo: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Prazo: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Prazo: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Prazo: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Prazo: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Prazo: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Prazo: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LLAI01 - STARLIGHT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .